JPMorgan Chase & Co. Issues Positive Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Key Points

• JPMorgan raised Teladoc Health’s price target from $8 to $10 while maintaining a Neutral rating, implying approximately 17% upside from the reported $8.52 share price.
• Analyst sentiment remains mixed: five analysts rate TDOC Buy, ten rate it Hold, and one rates it Sell, producing a consensus Hold rating and $7.77 price target.
• Teladoc’s latest quarterly results exceeded expectations, with a smaller-than-forecast loss of $0.15 per share and revenue of $605.1 million, although revenue declined 3.4% year over year and the company remains unprofitable.

Teladoc Health (NYSE:TDOC - Get Free Report) had its price objective boosted by stock analysts at JPMorgan Chase & Co. from $8.00 to $10.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a "neutral" rating on the health services provider's stock. JPMorgan Chase & Co.'s target price points to a potential upside of 17.37% from the stock's current price.

A number of other research analysts have also recently commented on TDOC. Canaccord Genuity Group dropped their price target on Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Citigroup decreased their price objective on Teladoc Health from $11.00 to $7.50 and set a "neutral" rating for the company in a report on Monday, August 3rd. Needham & Company LLC restated a "hold" rating on shares of Teladoc Health in a research note on Thursday. Bank of America upped their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a "buy" rating in a report on Tuesday, July 7th. Finally, Stifel Nicolaus increased their target price on shares of Teladoc Health from $5.50 to $6.50 and gave the stock a "hold" rating in a research report on Thursday. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $7.77.

Teladoc Health Stock Down 2.4%

Shares of TDOC traded down $0.21 during mid-day trading on Friday, hitting $8.52. The stock had a trading volume of 8,158,447 shares, compared to its average volume of 5,112,266. The company has a market cap of $1.55 billion, a PE ratio of -9.91 and a beta of 2.14. Teladoc Health has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The company's fifty day simple moving average is $6.19 and its two-hundred day simple moving average is $6.47.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The firm had revenue of $605.10 million during the quarter, compared to the consensus estimate of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.52%. The firm's revenue was down 3.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.28) earnings per share. Equities analysts expect that Teladoc Health will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Charles III sold 17,805 shares of the business's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $6.10, for a total transaction of $108,610.50. Following the transaction, the chief executive officer directly owned 465,535 shares in the company, valued at $2,839,763.50. The trade was a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is currently owned by insiders.

Institutional Trading of Teladoc Health

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its stake in Teladoc Health by 1.3% during the first quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider's stock worth $44,066,000 after buying an additional 107,400 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in Teladoc Health during the 2nd quarter worth about $26,864,000. Pale Fire Capital SE raised its position in shares of Teladoc Health by 74.8% in the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock worth $18,522,000 after acquiring an additional 1,454,288 shares in the last quarter. Quantinno Capital Management LP raised its holdings in shares of Teladoc Health by 128.0% during the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock valued at $14,287,000 after purchasing an additional 1,471,631 shares during the period. Finally, Counterpoint Mutual Funds LLC grew its position in Teladoc Health by 1,017.4% in the 3rd quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider's stock valued at $9,571,000 after purchasing an additional 1,502,488 shares during the period. Institutional investors and hedge funds own 76.82% of the company's stock.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q3 results beat expectations. Teladoc reported a loss of $0.15 per share versus the $0.23 consensus loss, while revenue of approximately $605 million exceeded estimates by about 3.3%. Adjusted EBITDA reached roughly $79 million, near the high end of guidance. Teladoc Q3 loss and revenue results
• Positive Sentiment: Cash flow and loss quality improved. Investors responded favorably to stronger free cash flow and adjusted EBITDA, suggesting that Teladoc is making progress on cost control even as revenue declined about 3% year over year. Teladoc stock rebounds as cash flow improves
• Positive Sentiment: BetterHelp’s insurance strategy is gaining traction. BetterHelp generated $32 million in insurance revenue during Q3, and management expects the insurance-related business to reach an annualized run rate of at least $200 million. Teladoc also plans to repurchase convertible notes, potentially reducing financial obligations. Teladoc BetterHelp insurance and convertible notes plans
• Positive Sentiment: Deutsche Bank raised its price target to $11 from $10 and maintained a Buy rating, reinforcing the bullish reaction to the earnings report. Deutsche Bank Teladoc price target update
• Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average may amplify momentum, but these are trading signals rather than fundamental improvements.
• Negative Sentiment: Forward guidance remains mixed. Full-year revenue guidance of $2.4 billion matched consensus, but the FY 2026 EPS range of negative $0.95 to negative $0.75 brackets consensus at negative $0.81. Q4 revenue guidance also has a midpoint below analyst expectations, while the EPS range is wider and includes results below consensus.
• Negative Sentiment: Stifel raised its price target to $6.50 but retained a Hold rating, and Needham reaffirmed Hold. These targets remain well below recent trading levels, highlighting valuation and execution concerns. Stifel Teladoc rating

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.